Drug giants Pfizer, AstraZeneca in $100bn merger tussle (Update)

April 28, 2014 by Ben Perry

US drugs giant Pfizer wants a blockbuster merger with British rival AstraZeneca that will fuel cancer research, revealing on Monday that an informal approach worth almost $100 billion had been rejected.

Pfizer chairman and chief executive Ian Read said that a tie-up between two of the world's biggest pharmaceutical groups would "help to fight some of the world's most feared diseases, such as cancer".

It would also benefit the shareholders of both companies, he said.

AstraZeneca's share price surged by about 15 percent in response to Read's statement, bringing the company's market value to slightly above January's informal offer price of $99 billion.

AstraZeneca had yet to respond to Pfizer's statement, which comes as the global pharmaceutical sector is undergoing a huge shake-up to face the challenges of expiring patents for key brands and deep cuts to government healthcare spending worldwide.

On a broader front, big companies are showing renewed interest in takeover opportunities amid a new-found appetite for risk, driven by strong cash positions, and cheap money since the financial crisis

Reports of a potential tie-up between the two drugs groups had first emerged one week ago.

In a statement issued to the London Stock Exchange, Pfizer said "it previously submitted a preliminary, non-binding indication of interest to the board of directors of AstraZeneca in January 2014 regarding a possible merger transaction".

It added: "After limited high-level discussions, AstraZeneca declined to pursue negotiations." Pfizer however stressed "its continuing interest in a possible merger transaction".

Pfizer to turn 'hostile'

Joshua Raymond, chief market strategist at City Index trading group, said Pfizer's statement indicated that the company was no longer interested in a friendly merger deal.

"Make no mistake, the confirmation today of Pfizer's interest is a declaration of its intention to now pursue a hostile merger.

"With AstraZeneca rebuking their attempts to negotiate, Pfizer has tried to create a buzz within AstraZeneca's leading shareholders to get them to force the issue with the current board.

"The board of AstraZeneca remains under pressure after falling sales and a failure to gain momentum for ... turnaround plans," Raymond said in a note to clients.

Pfizer said it had informally offered £46.61 ($78.4, 56.59 euros) per AstraZeneca share on January 5 in a cash and stocks offer, which valued the target company at £58.8 billion ($99 billion).

The US company said it had contacted AstraZeneca on Saturday "seeking to renew discussions" and was "considering its options" after AstraZeneca once more refused to take up the interest.

Read said on Monday that "patients all over the globe would benefit" from a merger, "in the form of potential new therapies that help to fight some of the world's most feared diseases, such as cancer".

He said: "The combination of Pfizer and AstraZeneca could further enhance the ability to create value for shareholders of both companies."

Rush of tie-ups

Speaking last Thursday, AstraZenenca chief executive Pascal Soriot said his company was on the look out for deals, while cautioning about major merger agreements.

Soriot, who said large acquisitions can be "very disruptive", spoke to reporters following publication of AstraZeneca's latest earnings update and after drugmakers Novartis and GlaxoSmithKline unveiled multi-billion-dollar deals also involving US group Eli Lilly.

The string of deals by the three giant healthcare groups will see Novartis sharpen its focus on the high-grossing cancer sector, GSK boost its share in vaccines and Eli Lilly strengthen its animal health unit.

Also last week, Valeant Pharmaceuticals offered to acquire Botox-maker Allergan for more than $45 billion.

Raymond said a merger would produce also a massive tax benefit for Pfizer.

"They are sitting on a burgeoning cash pile of multiple billions outside of the US, and would face a hefty tax bill to repatriate this cash," he noted.

AstraZeneca is looking to push ahead with new treatments for cancer, respiratory disease and diabetes after announcing a plunge in profits for the first quarter, hit by generic competition following the loss of exclusivity for some of its key drugs.

AstraZeneca is shedding also around 5,000 jobs under a three-year cost-cutting programme due to end in 2016.

Explore further: Novartis reshapes business with GSK, Lilly deals (Update)

Related Stories

Novartis reshapes business with GSK, Lilly deals (Update)

April 22, 2014
Swiss pharmaceutical firm Novartis AG launched a major overhaul of its business Tuesday, unveiling a series of multibillion-dollar deals with Britain's GlaxoSmithKline PLC and the U.S.'s Eli Lilly & Co. that heralds more ...

Shares of Indian units of Pfizer, Wyeth jump on merger approval

November 25, 2013
Shares of the Indian units of US pharmaceutical firms Pfizer and Wyeth soared Monday, after the pair approved a merger plan which would create India's ninth largest drug company.

Eli Lilly to buy part of Novartis for $5.4 bn

April 22, 2014
US pharmaceutical giant Eli Lilly said Tuesday it has reached an agreement to acquire the animal health division of Novartis of Switzerland for $5.4 billion (3.9 billion euros).

AstraZeneca pays $4.1 billion for diabetes buyout (Update)

December 19, 2013
Anglo-Swedish drugmaker AstraZeneca PLC will buy out Bristol-Myers Squibb Co.'s stake in their partnership to develop and sell diabetes drugs in a deal worth $4.1 billion—seizing an opportunity to serve the projected explosion ...

AstraZeneca settles legal dispute with Watson (Update)

March 25, 2013
(AP)—Anglo-Swedish pharmaceutical company AstraZeneca has settled a patent dispute with Watson Laboratories, Inc., removing a threat against its top-selling cholesterol-control drug, Crestor.

New clinical trial launched for advance lung cancer

April 17, 2014
Cancer Research UK is partnering with pharmaceutical companies AstraZeneca and Pfizer to create a pioneering clinical trial for patients with advanced lung cancer – marking a new era of research into personalised medicines ...

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.